**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 62414

**Manuscript Type:** MINIREVIEWS

**COVID-19: Where is the treatment?**

Sabeerabi B *et al*. Treatment for COVID-19

Bonala Sabeerabi, Sarojamma Vemula, Ramakrishna Vadde, Ganji Purnachandra Nagaraju

**Bonala Sabeerabi,** Department of Biochemistry, Biostandups, Hyderabad 500039, Telangana, India

**Sarojamma Vemula,** Department of Microbiology, Government Medical College, Anantapur 515001, Andhra Pradesh, India

**Ramakrishna Vadde,** Department of Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa 516003, Andhra Pradesh, India

**Ganji Purnachandra Nagaraju,** Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, United States

**Author contributions:** All authors are equally contributed.

**Corresponding author: Ganji Purnachandra Nagaraju, DSc, PhD, Instructor,** Department of Hematology and Medical Oncology, Emory University, 1365 Clifton Road Winship C #3025, Atlanta, GA 30322, United States. pganji@emory.edu

**Received:** January 7, 2021

**Revised:** March 4, 2021

**Accepted:** May 17, 2021

**Published online:** May 24, 2021

**Abstract**

Even though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is related to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), identifying effective and safe therapeutic strategies remains challenging. In search of finding effective treatments to eradicate the virus and improve disease symptoms, scientists are exploring possible therapies such as anti-viral, anti-malaria, immune therapy, and hormone treatments. However, the efficacy of these treatments was not validated on either SARS-CoV or MERS-CoV. In this study, we have reviewed synthetic evidence achieved through systematic and meta-analysis of therapeutics specific for SARS-CoV-2 and observed that the use of the above-mentioned therapies had no clinical benefits in coronavirus disease 2019 patients and, conversely, displayed side effects.

**Key Words:** COVID-19; Meta-analysis; Therapeutics; Anti-viral drugs; Immune therapy; Corticosteroids

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Sabeerabi B, Vemula S, Vadde R, Nagaraju GP. COVID-19: Where is the treatment? *World J Clin Oncol* 2021; 12(5): 309-322

**URL:** https://www.wjgnet.com/2218-4333/full/v12/i5/309.htm

**DOI:** https://dx.doi.org/10.5306/wjco.v12.i5.309

**Core Tip:** The outcomes from these studies, supporting the use of anti-corona therapies, remain mostly inconclusive and uninspiring, so far, because of the lack of evidence, methodological flaws, missing data entries, risk of bias, publication bias, heterogeneity of outcomes and the number of subjects included in the respective studies. High-quality data from more stringent studies involving large samples, particularly randomized clinical studies, and caution on when to employ the treatments are needed.

**INTRODUCTION**

From the establishment of PRISMA guidelines in 2009, it is obvious that the importance and use of meta-analysis is growing at an unprecedented rate in scientific explorations. Meta-analysis is a statistical approach for evaluating the pooled data from various original research studies to provide quantitative, concise, and up to date knowledge[[1](#_ENREF_1)]. Meta-analysis provides research outcomes *via* scientific synthesize through investigating the size of the effect or overall effect. This statistical analysis played a profound role in providing an evidence-based tool and in clarifying, superficially, paradoxical outcomes in several scientific domains; thus, eliminating controversy and criticism over particular study outcomes[[1](#_ENREF_1)]. Though the term “meta-analysis” was born in the 1970s, currently the use of this tool has extended from medical sciences to other fields like physiology, conservation, evolution and ecological sciences; this infiltration strongly suggests that meta-analysis is replacing narrative reviews as an alternative, objective and instructive way of recapping biological concepts[[2](#_ENREF_2)]. Synthesis of evidence from meta-analysis should become a common practice in order to maximize the value of scientific study in primary experimental research. Meta-analysis is very crucial to make progress in biological, medical, policy and conservation applications since these fields are greatly dependent on evidence-based outcomes[[1](#_ENREF_1),[2](#_ENREF_2)]. Meta-analysis has aided in finding patterns, building projections, achieving generalizations and creating evidence-based conclusions in several research branches including oncology[[3](#_ENREF_3)], obesity[[4](#_ENREF_4)], pathophysiology[[5](#_ENREF_5)], drug discovery[[6](#_ENREF_6)] and diagnostic test accuracy[[7](#_ENREF_7)]. Moreover, the exploration of corona virus and its therapeutic choices using meta-analysis is growing, even though the amount of original research articles over the topic are limited and these statistical outcomes are creating a corner to reach vast generalizations. Very recently, multiple meta-studies have reported their evidence-based outcomes with traditional medicines, anti-viral drugs, immune boosters, immunotherapy and use of hydroxychloroquine as treatment options in association with corona viral infection[[8-12](#_ENREF_8)]. These meta-studies hoped to use existing evidence and provide the likability of treatment success on novel corona virus.

In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) in the city of Wuhan, China, spread across the globe within a short period of time and became the latest public health emergency at the international level[[13](#_ENREF_13)]. As of June 15, 2020, COVID-19 has been recognized in 213 countries and territories, with a total of 7805148 confirmed positive cases and with a total of 431192 fatalities. Infection control and recovery measures are necessary to prevent the current pandemic situation. It has been observed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can bring asymptomatic, systemic or respiratory disorders in subjects infected with it. COVID-19 disease is characterized by serious upper respiratory illness including lung failure and pneumonia[[14](#_ENREF_14)], where the cause of disease was COVID-19 virus [World Health Organization (WHO) named on February 11, 2020] and has been identified as a new novel coronavirus, which is now confirmed as SARS-CoV-2[[13](#_ENREF_13),[14](#_ENREF_14)]. Earlier two major outbreaks of corona viruses occurred, namely Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV, posing a great threat to public health; however, these diseases were not deemed as pandemics. The SARS-CoV-2, which emerged in 2002, is a zoonotic corona virus similar to that of SARS-CoV[[14](#_ENREF_14),[15](#_ENREF_15)]. As COVID-19 has triggered enormous human casualties and serious economic losses globally, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. COVID-19 has caused a disturbed lifestyle, colossal human deaths, and pressing industrial losses globally and within a short period. This outbreak calls for urgent and effective measurements, anti-viral therapeutics, and the establishment of effective strategies to restrain the virus. Several scientific explorations, particularly meta-studies are providing a great amount of evidence to adapt various therapeutic choices including immune therapy, anti-viral drugs and even the use of traditional medicines to treat COVID-19 infection. Hence, in the current review, we aim to review the status of all meta-studies published from 2019-2020 focusing on therapeutic options for COVID-19 to highlight future directions in the development of safe and successful therapeutic agents to prevent the viral disease (Figure 1).

**The pathogenesis of COVID-19**

Though the initial transmission of COVID-19 was reported in Wuhan City, China, the actual source, reservoirs or intermediate carriers of the virus are still unknown. The latest COVID-19 viral genome has 88% similarity with SARS-CoV, which are derived from bats. The similarity also suggests that no birds or reptiles can host this virus except mammals[[16](#_ENREF_16)]. Though the information on primary reservoirs of COVID-19 remain unclear, the transmission from person-to person *via* virus laden released during sneezing, coughing, or direct contact with infected person was reported[[17](#_ENREF_17)]. Studies also confirmed that there is no transmission of virus from mother to child during pregnancy[[18](#_ENREF_18)]. The first step of viral infection is the binding of viral spikes with cell-surface receptors of host cells and subsequent fusion with the plasma membrane, specifically on the epithelial cells of the lungs. Studies have investigated and confirmed that COVID-19 shares similarity in the receptor-binding domain of the SARS-CoV and interacts with angiotensin-converting enzyme 2 receptor (ACE2) present on the upper respiratory tract cells to gain invasion into the host system[[17](#_ENREF_17)]. Moreover, a very recent study identified a group of human’s proteins able to interact with SARS-CoV-2 proteins and these host proteins exhibit a range of functions at the cellular level (including DNA replication, vesicle traffic, mitochondrial, nuclear transport, cytoskeleton, lipid modifications, epigenetic regulators and ubiquitin ligases)[[19](#_ENREF_19)].

It has been observed that SARS-CoV-2 can bring asymptomatic, systemic or respiratory disorders in subjects infected with it[[20](#_ENREF_20),[21](#_ENREF_21)]. An incubation period of 5.8 d was seen in patients infected with COVID-19 with no symptoms and only after this incubation phase, the symptoms of COVID-19 appear from mild to life-threatening illness within 6 to 41 d, with an average of 14 d[[20](#_ENREF_20),[21](#_ENREF_21)]. The appearance of symptoms after the incubation period depends on age as well as the individual’s immune system. The common systemic symptoms of COVID-19 infection are fever, dry cough, fatigue, headache, dyspnoea, gastrointestinal symptoms, lymphopenia and haemoptysis[[22](#_ENREF_22)]. The life-threating respiratory disorders such as pneumonia, respiratory distress syndrome, acute cardiac injury, serum SARS-CoV-2 viral load (RNAaemia), and prevalence grand-glass opacities in lungs were also reported[[22](#_ENREF_22)]. Patients infected with COVID-19, who experienced breathing difficulties and pneumonia, also had high levels of pro-inflammatory cytokines and chemokines (granule cell stimulating factor, granulocyte-macrophage colony-stimulating factor, interleukin (IL)1-β, IL1RA, IL7/8/9/10, fibroblast growth factor 2, interferon γ, IP10, MCP1, MIP1α/β, platelet-derived growth factor B, tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor A) in the serum; these cytokines and chemokines are related in promoting disease progression[[23](#_ENREF_23)]. At present, the world is not prepared to face pandemics like COVID-19 and is suffering from its consequences. Until today, there are no functional therapeutic drugs to treat the COVID-19 viral infection. However, COVID-19 patients are receiving supportive care, oxygen supply *via* ventilators and fluid management to overcome symptoms; nonetheless, there are tremendous efforts for vaccine development are undergoing. The global research community and pharma industries are working closely to find a cure for COVID-19 yet remain unsuccessful due to lack of existing evidence about druggable agents, which can provide a safe and sustainable cure for COVID-19 infection. The one possible way to accelerate the discovery process is to look for relatable drug agents that are primarily used in pneumonia, SARS-CoV and MERS-CoV infections. A wide variety of druggable agents or strategies those are known to work against deadly viruses such human immunodeficiency virus and Ebola can also be adapted; however, a clinical validation is needed. To accelerate the discovery of a druggable agent, a clear validation and generalizations of existing information on corona viruses and their killer is useful. To achieve such goals meta-studies are the only source. Hence, in the following sections, we will highlight the evaluations of meta-studies conducted on various possible drug agents against COVID-19 to find the most suitable and reliable cure.

***Meta-analysis and COVID-19 therapeutics***

The synthesis of scientific results from pooled data can help us to compare existing results in order to comprehend epidemiology, mortality, management choices, risk assessment and efficiency of prophylactic strategies against COVID-19. When we set the aim to explore the meta-studies on COVID-19 treatment efficiencies, we were unable to find such studies in the databases. The reason could be due to the lack of sufficient or compelling experimental evidences or clinical investigations to perform meta-analysis on prophylactic strategies against COVID-19. However, a few groups tried to find the pattern in aetiology, comorbidities and pathological variations and risk factors of COVID-19 at length[[24-27](#_ENREF_24)]. Zhong *et al*[[28](#_ENREF_28)] tried to perform systematic cum meta-analysis on the efficiency and safety of prophylactic strategies against COVID-19. Since the available data on such a topic was less, they tried to evaluate SARS-CoV and MERS-CoV therapies to find relatable and promising treatment options for SARS-CoV-2 infection[[28](#_ENREF_28)]. In their meta study, antiviral drugs such as lopinavir/ritonavir, ribavirin and anti-malaria drug hydroxychloroquine based clinical data on SARS-CoV, MERS-CoV and COVID-19 was evaluated and found that, altogether, there was an improved mortality rate and reduced clinical development and radiographical improvement but no clear conclusion on the eradication of virus, the incubation phase, the prevalence of acute respiratory disease syndrome and adverse events[[28](#_ENREF_28)]. However, a subgroup evaluation confirmed that use of ribavirin and corticosteroids in combination had a positive effect on reducing mortality and hydroxychloroquine, which was demonstrated on radiographical outcomes alone. In addition, use of a combination of lopinavir/ritonavir exhibited better eradication of the virus and improved radiographical appearances with a low prevalence of acute respiratory disease syndrome. Keeping the side effects of the drug combination tested into consideration, the quality of verification on most end results were very low and disappointing[[28](#_ENREF_28)]. Though the meta-analysis failed to draw direct conclusions, due to the heterogeneity and low quality of evidence and indications, the study is still useful for clinicians to thoroughly acknowledge the dos and don’ts of individual anti-coronavirus agents on efficacy and safety. On the other hand, Etoom *et al*[[29](#_ENREF_29)] recently commented on one meta study published by Hu *et al*[[30](#_ENREF_30)] titled “Prevalence and severity of COVID-19: A systematic review and meta-analysis”. The former group thinks a much deeper and careful statistical strategy is needed to evaluate the available evidences on COVID-19. They also suggested that meta-analysis data should be made available, especially in the case of COVID-19, since the number of research explorations are growing immensely and performing new meta-analysis would be easier and quicker[[29](#_ENREF_29),[30](#_ENREF_30)]. We believe, at this stage meta-studies on COVID-19 and therapeutics efficiency might take time because of the lack of sufficient empirical data and since the rate of research investigations are actually yielding low successful outcomes. Nonetheless, we look forward to see an increase in meta-studies aimed at COVID-19 research outcomes. It is noteworthy to mention that, though there were no meta-studies on efficiency of prophylactic strategies against COVID-19, there are a few systematic reviews on the same subject. Meta-analysis and systematic reviews stand atop in estimating the quality of evidence known as “evidence pyramid”. Systematic review does not require statistical analysis, but provides a comprehensive synopsis of scientific literature to a specific research question.

***Systematic reviews and COVID-19 therapeutics***

In order to curtail the current SARS-CoV-2 global crisis, rapid diagnostics and effective therapeutics are the key potential interventions, which are currently occurring. Moreover, the lessons from previous outbreaks have shown that earlier therapeutics can still be questionable for the use in the current pandemic. Among the ongoing clinical investigations, some of them are testing against SARS-CoV and MERS-CoV while the rest are focused on SARS-CoV-2; however, currently, there is no success of effective therapeutics specific to SARS-CoV-2. The ways to eradicate SARS-CoV-2 include anti-viral drugs, immune therapy, immune boosters, vaccines, anti-malarial drugs, monoclonal antibodies and convalescent plasma, which are majorly monitored by pharma and research investigators. The ultimate goal is to develop anti-corona therapeutics; to accelerate such processes, every effort made is accountable and systematic generalization of such progresses play an important role in deciding the efficacy and safety of individual anti-coronavirus agents. In this hour of need what we want is a magic bullet to stop COVID-19; however, it is not easy to identify, testify, validate and get approval for such magic bullet. Constant efforts from biologists, pharmacists and policy makers are needed to evaluate the efficacy of anti-corona therapies and we are running out of time. We have highlighted the evidence collected through systematic analysis on anti-corona therapies to bring a comprehensive, evidence-based evaluation under one roof to further increase the understanding on the current success rate of anti-corona therapies. An overview of some of the most relevant systematic reviews and meta-analysis studies conducted on therapeutic strategies specific to COVID-19 are given in Table 1.

***Systematic evaluation of anti-viral drugs specific to SARS-CoV-2***

The ongoing antiviral drugs against COVID-19 are mostly similar to MERS-CoV and SARS-CoV-1 studies. A recent study conducted a systematic review on the current clinical settings of antiviral therapies against COVID-19[[8](#_ENREF_8)]. The study also conducted a similar evaluation on MERS-CoV and SARS-CoV-1 studies to filter potential antiviral drugs. In their analysis, only one clinical investigation involving lopinavir-ritonavir in management of COVID-19 was found, where the treatment had no benefit in 199 severe COVID-19 patients[[8](#_ENREF_8)]. It is noteworthy to mention that other observational studies, where anti-viral drugs such oseltamivir, lopinavir-ritonavir, lianhuaqingwen capsule, arbidol and interferon were used in the management of COVID-19, could not yield positive conclusions due to the lack of data recording and appropriate sample sizes[[8](#_ENREF_8)]. Most interestingly, the team could not find any clinical settings where the effects of anti-viral drugs were tested against MERS-CoV and SARS-CoV-1 infections[[8](#_ENREF_8)]. From the above conclusions, we believe that the current pandemic is more challenging to curb and will be difficult and even more challenging to develop an ideal anti-viral drug to manage severe COVID-19 diseases. Another team also aimed to evaluate the prophylaxis of anti-retroviral drugs on COVID-19 using systematic review to generate strong evidence to support anti-viral drugs as the first line of treatment. They reported the availability of 21 observational studies and two randomized trials, which showed the end results on the use of lopinavir-ritonavir on MERS-CoV, SARS-CoV-1, and COVID-19 patients[[31](#_ENREF_31)]. From their evaluation, it was suggested that there were no clinical benefits from randomized trials, no inconclusive outcomes from observational studies and a low body of evidence across all major end points, indicating that the use of lopinavir-ritonavir anti-viral drugs as the first line of treatment is not efficient on COVID-19 patients[[31](#_ENREF_31)]. The team highlighted that reliability of the proof of end results across MERS-CoV, SARS-CoV-1, and COVID-19 is very low. They also suggested that, in addition to small sample size, the dose, duration and timing of the treatment was not uniform. Moreover, a combination of antiviral drugs along with other interventions may have given rise to the disclosed outcomes[[31](#_ENREF_31)]. Though both studies differed on trivial aspects of anti-viral drug efficacy against COVID-19, MERS-CoV and SARS-CoV-1 infection, the studies did agree on one common finding, that the use of lopinavir-ritonavir on severe COVID-19 is not efficient. Currently, nearly twenty-five clinical trials are registered and each of the plans are investigating the efficacy and safety of anti-viral agents, including cobicistat, ritonavir, darunavir, lopinavir-ritonavir and tenofovir alafenamide fumarate.

***Systematic evaluation of immune therapy specific to SARS-CoV-2***

The reason behind choosing immune therapy against COVID-19 is because of the presence of clinical features, such as lymphopenia, increased inflammatory cytokines, chemokines and reduced IFN-γ expression in T cells, which indicate suppression of the host immune system against sever COVID-19 infections[[32](#_ENREF_32)]. The strategies to boost the host immune system through neutralizing antibodies or vaccines are focused on provoking the immune system to fight against COVID-19. However, in the case of COVID-19, the most popular known immune therapy is hyperimmune immunoglobulin transfusion or plasma therapy with nearly 48 studies aimed to evaluate hyperimmune immunoglobulin transfusion or plasma therapy for COVID-19 infected people. A rapid systematic review conducted by Valk *et al*[[33](#_ENREF_33)] assessed the risks and benefits of using plasma transfusion as a potential immune therapy for COVID-19[[33](#_ENREF_33)]. They reported that the majority of studies identified adverse side effects (grade 3/4) and that the quality of the reported data was low on plasma transfusion. The data deposited on plasma transfusion studies was highly inconsistent, making it difficult to draw outcomes with certainty[[33](#_ENREF_33)]. Moreover, some of the controlled non-randomised or randomised controlled investigations are still occurring and have not reported any data regarding the harms and benefits of convalescent plasma therapy[[33](#_ENREF_33)]. Though the plasma therapy looks promising, the current, global systematic analysis it is not efficient and safe. However, the effectiveness and safety of plasma transfusion remain elusive when compared with other immune therapeutic strategies.

Another study performed a systematic review on probable immune therapies for COVID-19. In this study, the authors included evidences from MERS-CoV, SARS-CoV and SARS-CoV-2 infections, in which the safety and efficacy of immunotherapy was investigated[[34](#_ENREF_34)]. The highlights of the study primarily come from a single ethnic group (in China); evidence was reported in clinical settings, where the use of plasma therapy (300 subjects), hyperimmune immunoglobulin transfusion (80 subjects), thymosin in combination with camrelizumab (120 subjects) and tocilizumab (188 subjects) against COVID-19 were tested[[35](#_ENREF_35)]. Though the outcomes of the studies with plasma therapy or hyperimmune immunoglobulin transfusion reported clinical improvements in COVID-19 patients, the evidence to support such therapies fails to provide certainty and demands for further investigations on a large-scale and more diverse population[[34](#_ENREF_34)]. Moreover, the end outcomes of thymosin/camrelizumab combination therapy and tocilizumab against COVID-19 have yet to be tested. However, the study recommends to test the efficacy and safety of interventions like viral-vectors, vaccines, nanoparticles, and monoclonal antibody against COVID-19 infection, since those have been tested for SARS-CoV in non-clinical settings[[34](#_ENREF_34)]. Another study performed a systematic analysis to determine the efficacy and safety of immune suppressive/stimulating drugs, such as non-steroidal anti-inflammatory drugs, TNF-α inhibitors, IL-6 inhibitors and Janus kinase/signal transducers and activators of transcription pathway inhibitors. These studies reported that no definite supporting evidence is available from clinical investigations; hence, they recommend clinical investigations using such drugs as promising immune therapeutics, since their efficacy was proved in *in vitro* studies[[12](#_ENREF_12)]. Whatever approach was adapted by the above-discussed systematics, the end outcome, in terms of using immune therapy for COVID-19, remains dark. The literature is filled with reviews discussing the many possible approaches to prevent COVID-19, but what we need at this moment is more evidence-based studies than narrative opinions.

***Systematic evaluation of anti-malaria drugs specific to SARS-CoV-2***

In an unusual way, the use of anti-malarial drugs to cure viral infections has become quite popular lately. Malaria is caused by a parasite, *Plasmodium,* and COVID-19 disease is caused by the human corona virus; there are no structural or pathological similarities between the virus and the parasite. However, they both definitely increase body temperature upon infection. The earlier use of anti-malaria drug, such as chloroquine, against human corona viral infections in mouse models was reported in 2009[[36](#_ENREF_36)]. Due to the public health emergency from SARS-CoV-2, every possible means to prevent viral infections was predicted and being tested. Hence, anti-malaria drugs are currently one of the drugs being evaluated for their efficacy and safety against SARS-CoV-2 in humans. A systematic review conducted found evidence regarding the effectiveness of anti-malaria drugs as anti-viral drugs to prevent SARS-CoV-2[[37](#_ENREF_37)]. The team reported seven clinical trials, which were evaluating hydroxychloroquine/ chloroquine as therapy for SARS-CoV-2, as complete. The end outcomes of the study suggest that both hydroxychloroquine/chloroquine were effective compared to supportive care or anti-viral drug treatment of SARS-CoV-2[[37](#_ENREF_37)]. However, the outcomes are not reliable, since the evaluated studies has methodological flaws and risk for bias, indicating a lack of evidence to support anti-malaria drugs on SARS-CoV-2. However, hopefully, the data from ongoing trials may provide some evidence in the future[[37](#_ENREF_37)]. Another study found similar outcomes upon systematic revision of prophylactic outcomes of hydroxychloroquine and chloroquine against SARS-CoV-2; here, the team concluded that there is a lack of evidence to support hydroxychloroquine and chloroquine routine use and there are potential safety issues, which need to be further evaluated[[38](#_ENREF_38)]. Another study screened nearly 663 articles and 12 clinical trials, validated the use of hydroxychloroquine and chloroquine against SARS-CoV-2 and found that some of the studies had better clinical outcomes with hydroxychloroquine or combination of azithromycin/hydroxychloroquine use in COVID-19 patients. However, these studies also had major flaws in their methodology. Moreover, a few studies showed adverse and opposite outcomes with hydroxychloroquine[[39](#_ENREF_39)]. Similarly, another study reported similar observations and came up with a few recommendations, like employing a proper approach based on Monitored Emergency Use of Unregistered Interventions or WHO guidelines in upcoming clinical settings, especially with the use of anti-malaria drugs[[40](#_ENREF_40)]. We also believe that a better-quality and stringent studies design and inter-relatable data from clinical trials originating across the globe are needed to clear the air regarding the use of hydroxychloroquine and chloroquine against SARS-CoV-2. It is noteworthy to mention that not only systematic reviews but also meta-analyses confirm the ineffective role of hydroxychloroquine in treating COVID-19 patients[[9](#_ENREF_9)]. The Meta study confirms that there was no effect on viral eradication and a significant mortality rate was seen in COVID-19 patients treated with hydroxychloroquine[[9](#_ENREF_9)].

***Systematic evaluation of corticosteroids specific to SARS-CoV-2***

Steroid hormones exhibit an inhibitory role on inflammation, when used in viral pneumonia; hence, many physicians recommended corticosteroid therapy as a possible treatment for patients with COVID-19. Though corticosteroid does not affect the virus directly, this therapy may help in managing severe inflammation and regulate homeostasis. Thousands of people infected with COVID-19 were treated with corticosteroid alone or in combination with anti-viral drugs. Meta-analysis and systematic reviews conducted on finding evidence in support of corticosteroid therapy for SARS-CoV-2 suggested that hormone therapy is ineffective and provokes adverse side effects.

A study by Yang *et al*[[41](#_ENREF_41)] found that only patients with severe COVID-19 require hormone therapy and routine use of corticosteroid; these patients showed an increased mortality rate, bacterial infection and low blood potassium levels[[41](#_ENREF_41)]. A caution must be taken while considering corticosteroid as a therapeutic option for mild symptoms[[42](#_ENREF_42)]. Overall, the study finds inconclusive results, such as sample size, risk of bias in outcomes and the lack of data from multi-centre clinical trials[[41](#_ENREF_41)]. A different meta-analysis ruled out the safety and efficacy of corticosteroids in SARS-CoV-2 infections. When they tested the virus’ clearing effect by corticosteroids, they observed a slow virus clearing rate in two studies[[43](#_ENREF_43)]. The meta-analysis concludes that there was no improvements in the death rate or the length of stay, which was accompanied by adverse effects[[43](#_ENREF_43)]. Due to predominance of observational trials in the meta-study, a demand for confirmation from randomized trials to overcome the publication bias is needed[[43](#_ENREF_43)]. Additional studies also concluded that the current evidence does not fully recommend the use of corticosteroids in SARS-CoV-2 infections; however, a few outcomes recommend the use of methylprednisolone to decrease the mortality rate in severe SARS-CoV-2[[44](#_ENREF_44),[45](#_ENREF_45)].

***Other notable mentions***

While we discussed the most popular strategies employed in treating COVID-19, it is also important to explore other strategies employed in curing SARS-CoV-2 infection, such as remdesivir, anti-hypertension drugs and Traditional Chinese Medicine. Remdesivir is a broad-spectrum, anti-viral nucleotide analogue that has gained significant attention lately. In preclinical studies, remdesivir has been known to block a range of corona viruses and improve lung function therapeutically; however, the efficacy of remdesivir in COVID-19 patients remains short and scattered. The drug remdesivir received approval to be used under "Emergency Use Authorization" against severe COVID-19 cases, but is still awaiting approval by Food and Drug Administration. A recent systematic review conducted assessed the current evidence on the efficacy and safety of remdesivir and found favorable evidence as a first line treatment option in SARS-CoV-2[[46](#_ENREF_46)]. The study reported that in order to confirm and recommend remdesivir as high quality and bias free, evidence from clinical settings is needed. Moreover, clinical settings should qualify with larger sample sizes, constrictive design and well-recorded data to synthesize an effective conclusion[[46](#_ENREF_46),[47](#_ENREF_47)]. Furthermore, the future is hopeful with these ongoing trials and these studies may provide effective evidence on the benefits of remdesivir in COVID-19[[47](#_ENREF_47)]. The second choice that was opted to treat SARS-CoV-2 infection was inhibitors of the angiotensin receptor or ACE, a possible way to block viral interaction with receptors on lung epithelia cells. Meta studies on Angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEIs/ARBs) inhibitor-based treatment on SARS-CoV-2 concluded that using inhibitors of ACEIs/ARBs can be continued but large studies such as randomised controlled trial are needed and additional evaluation on the relationship between polymorphism of ACE2 and its inhibitor is a must in the future investigations[[48](#_ENREF_48),[49](#_ENREF_49)]. On the bright side, the upcoming outcomes from clinical trials (NCT04312009 and NCT04311177) using anti-ARB drug (losartan) in COVID-19 hold promising insights. The third choice that was opted to treat SARS-CoV-2 infection was a combination of Western medicine with TCM. One study aimed to investigate the benefits and harms of herbal medicine and Western medicine over COVID-19[[50](#_ENREF_50)]. The amalgamated therapy rapidly increased the overall effective rate with better clinical outcomes in COVID-19 patients with zero side effects. However, additional evidence from randomized clinical trials may help to validate the benefits or harms of integrated medicine in the treatment of COVID-19[[50](#_ENREF_50)]. Another study also showed that integrated medicine has beneficial effects when compared to Western medicine alone. The combination therapy did not yield any adverse effects in COVID-19 subjects. The number of studies included quality of data but poor methodologies were adapted in tested studies; a demand for more evidence with good quality to make definite decisions about combination therapy is needed in the future[[11](#_ENREF_11)]. Effective vaccines are curial in the long-term to prevent rapid transmission of SARS-CoV-2 infections but developing vaccines is time consuming. However, the current crisis is pushing the limits of vaccine development and a few vaccines are being investigated in clinical trials right now. Table 2 provides the details of vaccines developed and their current clinical state specific to SARS-CoV-2. The preceding vaccines belong to DNA, RNA, inactivated viruses, recombinant viral spike proteins, dendritic cells, minigenes and viral vector-based systems. A vaccine developed by Oxford University and AstraZeneca is the most progressive one to enter phase III study settings; this vaccine serves as hope for a promising cure for SARS-CoV-2. Clinical investigations, clinical clearance and approval from the governing body are prerequisites for any drug, vaccines or therapeutic strategies created. Currently, apart from the ones discussed earlier, a wide range of anti-viral drugs, vaccines, cell therapies and anti-bacterial therapeutics are ongoing to determine the safety and efficacy specific to SARS-CoV-2.

***SARS-CoV-2 specific drug targets under clinical investigation***

Even though the success rate was low and search for suitable, relatable therapeutic drugs against SARS-CoV-2 continues with extensive hard work. In this section we focus on some of the possible upcoming therapeutics which are under early as well late stages of clinical monitoring. A pilot study pursing the benefits of using amniotic fluid ([NCT04319731](https://clinicaltrials.gov/ct2/show/NCT04319731?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=1)) or mesenchymal stromal cells from card tissues ([NCT04399889](https://clinicaltrials.gov/ct2/show/NCT04399889?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=4), [NCT04345601](https://clinicaltrials.gov/ct2/show/NCT04345601?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=5) and [NCT04276987](https://clinicaltrials.gov/ct2/show/NCT04276987?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=8)) for patients with COVID-19 and use of amniotic fluid was an approved strategies to minimize inflammation, tissues damage in humans. Use of rhDNase1 inhalation to trap neutrophils increased in circulation due to elevated inflammation is under evaluation against SARS-CoV-2 infection ([NCT04409925](https://clinicaltrials.gov/ct2/show/NCT04409925?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=2)). Anti-IL-6 antibody named Sarilumab has entered clinical evaluation as a potential mediator to interrupt cytokine-linked respiratory injury caused by SARS-CoV-2 infection ([NCT04386239](https://clinicaltrials.gov/ct2/show/NCT04386239?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=3)). Mouth or nose cleaning and gargling with povidone-iodine solution is currently undergoing clinical examination ([NCT04393792](https://clinicaltrials.gov/ct2/show/NCT04393792?term=pilot+studies&cond=COVID19&phase=04&draw=2&rank=6)), since povidone-iodine killed SARS-CoV-2 virus effectively in *in vitro* studies[[51](#_ENREF_51)]. A phase III study aimed to rule out dosing with Sildenafil tablets in SARS-CoV-2, since it was approved by WHO for the prevention of pulmonary arterial hypertension ([NCT04304313](https://clinicaltrials.gov/ct2/show/NCT04304313?term=pilot+studies&cond=COVID19&phase=23&draw=2&rank=2)). A Tyrosine kinase inhibitor, Imatinib mesylate blocked inflammatory responses in invitro, *in vivo* and in few clinical trials, is under further examination in a phase III trial on SARS-CoV-2 and hoping to observe reduction in disease severity and inflammation ([NCT04422678](https://clinicaltrials.gov/ct2/show/NCT04422678?term=pilot+studies&cond=COVID19&phase=23&draw=2&rank=3)). Baricitinib, anti-Janus kinase inhibitor was approved to treat rheumatoid arthritis earlier and preclinical studies confirm that it can lower or prevent entry of viruses in to epithelia cells and reduce cytokine release, is under phase III clinical monitoring to use on SARS-CoV-2 ([NCT04320277](https://clinicaltrials.gov/ct2/show/NCT04320277?term=pilot+studies&cond=COVID19&phase=23&draw=2&rank=4)). The use of repurposed bacterial mucosal vaccines Bactek-MV130 in the form of spray is undergoing phase III trial to provide benefits for COVID-19 induced mild pneumonia ([NCT04363814](https://clinicaltrials.gov/ct2/show/NCT04363814?term=pilot+studies&cond=COVID19&phase=23&draw=2&rank=5)). Based on preclinical evidences where increased circulatory Vascular Endothelial Growth Factor was seen in COVID-19 subjects, anti-vascular endothelial growth factor drug namely Bevacizumab (FAD approved to treat certain cancers), is being tested in critical or severe patients with COVID-19 pneumonia ([NCT04275414](https://clinicaltrials.gov/ct2/show/NCT04275414?term=pilot+studies&cond=COVID19&phase=23&draw=2&rank=7)). Ifenprodil, a drug used to inactivate activated neutrophils and T-cells is under phase IIb/III trial to discover the safety and efficacy in the treatment of SARS-CoV-2 infection ([NCT04382924](https://clinicaltrials.gov/ct2/show/NCT04382924?term=pilot+studies&cond=COVID19&phase=23&draw=2&rank=10)). There is no recorded evidence from all the trials motioned above, so we do not know whether anti-inflammatory drugs, rheumatoid arthritis and anti-septic solutions have any benefits in COVID-19 patients. Noteworthy to mention that the above detailed investigations are based on the evidence gathered from preclinical studies and the benefits of using these repurposed medications against COVID-19 need evidence from these study outcomes. Moreover, the safety and efficacy of these drugs on COVID-19 are forthcoming and we hope the outcomes from these studies provide conclusive, bias free evidences. It seems the new players under investigation are mainly to treat SARS-CoV-2 symptoms and have zero effect on viral load, except for povidone-iodine, which was known to eradicate SARS-CoV-2. The world is eagerly dependent on scientific and pharma community for the discovery of magic bullet to treat COVID-19.

***SARS-CoV-2 therapeutic challenges and anticipations***

In spite of the worldwide distress, no drug or vaccines is available under approval to treat SARS-CoV-2 infection. So far, clinical reports and synthetic evidence show that reusing of existing anti-viral, anti-malaria, immune stimulators and corticosteroids on COVID-19 disease has been unsatisfactory and unsafe. In order to escalate the identification and validation of anti-SARS-CoV-2 medicine, use of computer based high through put data analysis in finding suitable drug targets is recommended. A broad range of anti-viral agents in preclinical and clinical settings must be evaluated for their safety and efficacy against SARS-CoV-2. We believe that use of repurposed medicines for COVID-19 are going to be part of short-term strategy. In spite of the fact that these relatable treatment options have been prioritized to treat SARS-CoV-2 and the outcomes are biased. These uncovering’s highlight an immediate call for novel anti-corona medicines specific to SARS-CoV-2 virus. In the current urgency there are several challenges and overcoming those challenges is crucial in developing novel anti-SARS-CoV-2 medications. One such hurdle is collection of evidence from preclinical experiments, which is expensive and time-dependent. In the absence of preclinical data, computer-based analysis of target profiling allows either to validate or invalidate the use of predicted drug; permits to accelerate invention of novel and beneficial therapeutics against SARS-CoV-2. Though the operating cost is reduced, the safety profile of those computer-generated targets must be validated at least in clinical settings. Another limitation faced by scientist is the availability of suitable study models (cells, mice and primates) to investigate the virus-host interaction and evaluate the potency of anti-SARS-CoV-2 drugs. In addition, BSL3 Laboratories with suitable study models are very few and conducting experiments in such environments is technically difficult. The development of host-based and/or SARS-CoV-2 based clinical inventions must be prioritized since only one or two of drugs will pass through clinical settings. Toxicity, dosage, availability of drug delivery routes and some other limitations make these drugs to pass through the clinical stage. Normally, the development and clinical approval of vaccine needs more than 10 years of time and efforts, however, vaccine development programs against SARS-CoV-2 are breaking the convectional norms and working hard to launch safe and effective SARS-CoV-2 vaccines as early as possible. It can be more challenging to treat COVID-19 diseases, if the virus develops genetic mutations and/or drug resistance during treatment. Studies have reported presence of 93 possible mutations and among them majority of mutations were missense mutations and the genome of SARS-CoV-2 was found to be highly conserved[[52](#_ENREF_52)]. Also, patients with underlying health issues such as diabetes, cancer, renal failure and women with pregnancy need exceptional care. In addition, management of COVID-19 patients has become challenging due to lack of sufficient medical staff, availability of drugs, subject recognition's, isolation and implication of control procedures and delivery of personalized care towards COVID-19 patients. New Zealand and few Asian countries managed to contain COVID-19 transmission effectively while compared with most of developed countries like United States and Europe. As the epidemic advances, hunger amid poor countries, influence of lock down on mental status of children and adults may increases. To avoid upcoming foreseeable future, systematic and unified approach is vital for managing COVID-19 epidemic. A single drug or a combination approach to preventing COVID-19 disease is needed to prevent mortality, restore the normal lifestyle and economic growth world-wide. The ideal drug must be able to kill virus load with zero or less toxicity in humans, affordable with minimum production time.

**CONCLUSION**

In this real-time crisis, a need for high-quality, bias-free, and effective evidence in eradicating the SARS-CoV-2 virus and reducing disease-associated symptoms with zero side effects is needed. Currently, the journal database is filled with narrative research and speculations with hypothetical reasoning; data on evidence-based research is limited. A shift in evidence originating from original research investigations and clinical studies with high-quality evidence is needed and this evidence may aid in progressing towards the development of effective and safe therapeutic options for SARS-CoV-2. Moreover, the systematic reviews and meta-studies are providing substantial evidence and clearing the air of bias for the public, physicians, and scientists. Drugs like hydroxychloroquine/chloroquine or remdesivir have gained a lot of attention in the public and the media; these drugs have also gained support from experts and are now being characterized as effective therapeutic drugs for SARS-CoV-2 but scientifically it is unwise to recommend these drugs to treat SARS-CoV-2 without caution. Currently, there are no effective anti-viral agents, immune therapy, or vaccines against SARS-CoV-2 but the future is filled with only hope. The current scientific evidence hold inconclusive outcomes because of the low number of studies conducted, low sample size, flawed study designs, publication bias, heterogeneity, missing data records, quality of evidence, ethnicity and presence of adverse effects. However, these flaws cannot stop current and future investigations to identify, characterize and validate possible therapeutic innovations specific to SARS-CoV-2.

***Future directions***

So far, considering the trajectory of COVID-19 pandemic, the primary need to control the transmission of the disease is to practice physical distancing, wearing masks, keeping hands off from surfaces, and washing them with proper detergent. These rules have somewhat provided the needed protection. The public is well aware of the facts to restrain themselves from being exposed. Developing surfaces or masks that can kill the virus within seconds once contact made could be a way to prevent highly transmissive virus-laden droplets that are just released. Coming to the scientific role in finding a cure, it is very crucial to understand the genetic profile of the virus at the molecular level and use this knowledge to build safe tools to screen, identify and develop therapeutics for the prevention and treatment of SARS-CoV-2. Currently, no laboratory in the world has whole virus to study in detail. Hence, it is only fitting to build the tools and resources that can be utilized for evaluating therapeutic efficacy. The journey to finding a vaccine or an anti-viral therapy specific to SARS-CoV-2 must start from the basic research integrated with advanced technologies such as artificial intelligence, computational biology, nanotechnology, and genome-wide association studies. The efforts made in the past to find the cure for COVID-19 though failed but provided immense knowledge on what not to practice and open new doors of possibility. Currently, applying a single therapeutic strategy, or even a combination of strategies is not enough to cure diseases including cancers and infectious diseases. In the end, prevention is better than a cure.

**REFERENCES**

1 **Gurevitch J**, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of research synthesis. *Nature* 2018; **555**: 175-182 [PMID: 29517004 DOI: 10.1038/nature25753]

2 **Nakagawa S**, Noble DW, Senior AM, Lagisz M. Meta-evaluation of meta-analysis: ten appraisal questions for biologists. *BMC Biol* 2017; **15**: 18 [PMID: 28257642 DOI: 10.1186/s12915-017-0357-7]

3 **Xu C**, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. *BMJ* 2018; **363**: k4226 [PMID: 30409774 DOI: 10.1136/bmj.k4226]

4 **Simmonds M**, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. *Obes Rev* 2016; **17**: 95-107 [PMID: 26696565 DOI: 10.1111/obr.12334]

5 **Fu Y**, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *JAMA Dermatol* 2018; **154**: 1417-1423 [PMID: 30422277 DOI: 10.1001/jamadermatol.2018.3631]

6 **Cipriani A**, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018; **391**: 1357-1366 [PMID: 29477251 DOI: 10.1016/S0140-6736(17)32802-7]

7 **Shin IS**. Recent Research Trends in Meta-analysis. *Asian Nurs Res (Korean Soc Nurs Sci)* 2017; **11**: 79-83 [PMID: 28688503 DOI: 10.1016/j.anr.2017.05.004]

8 **Yousefifard M**, Zali A, Mohamed Ali K, Madani Neishaboori A, Zarghi A, Hosseini M, Safari S. Antiviral therapy in management of COVID-19: a systematic review on current evidence. *Arch Acad Emerg Med* 2020; **8**: e45 [PMID: 32309809]

9 **Singh AK**, Singh A, Singh R, Misra A. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis." *Diabetes Metab Syndr* 2020; **14**: 589-596 [PMID: 32417708 DOI: 10.1016/j.dsx.2020.05.017]

10 **Kermali M**, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 - A systematic review. *Life Sci* 2020; **254**: 117788 [PMID: 32475810 DOI: 10.1016/j.lfs.2020.117788]

11 **Liu M**, Gao Y, Yuan Y, Yang K, Shi S, Zhang J, Tian J. Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis. *Pharmacol Res* 2020; **158**: 104896 [PMID: 32438037 DOI: 10.1016/j.phrs.2020.104896]

12 **Russell B**, Moss C, George G, Santaolalla A, Cope A, Papa S, Van Hemelrijck M. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. *Ecancermedicalscience* 2020; **14**: 1022 [PMID: 32256705 DOI: 10.3332/ecancer.2020.1022]

13 **Dariya B**, Nagaraju GP. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. *Cytokine Growth Factor Rev* 2020; **53**: 43-52 [PMID: 32409230 DOI: 10.1016/j.cytogfr.2020.05.001]

14 **Ahn DG**, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). *J Microbiol Biotechnol* 2020; **30**: 313-324 [PMID: 32238757 DOI: 10.4014/jmb.2003.03011]

15 **Rothan HA**, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun* 2020; **109**: 102433 [PMID: 32113704 DOI: 10.1016/j.jaut.2020.102433]

16 **Lu R**, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; **395**: 565-574 [PMID: 32007145 DOI: 10.1016/S0140-6736(20)30251-8]

17 **Wu P**, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, Cowling BJ, Leung GM. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. *Euro Surveill* 2020; **25** [PMID: 31992388 DOI: 10.2807/1560-7917.ES.2020.25.3.2000044]

18 **Chen H**, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020; **395**: 809-815 [PMID: 32151335 DOI: 10.1016/S0140-6736(20)30360-3]

19 **Malle L**. A map of SARS-CoV-2 and host cell interactions. *Nat Rev Immunol* 2020; **20**: 351 [PMID: 32303698 DOI: 10.1038/s41577-020-0318-1]

20 **Li Q**, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; **382**: 1199-1207 [PMID: 31995857 DOI: 10.1056/NEJMoa2001316]

21 **Wang W**, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol* 2020; **92**: 441-447 [PMID: 31994742 DOI: 10.1002/jmv.25689]

22 **Habibzadeh P**, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *Int J Occup Environ Med* 2020; **11**: 65-71 [PMID: 32020915 DOI: 10.15171/ijoem.2020.1921]

23 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

24 **Yang J**, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* 2020; **94**: 91-95 [PMID: 32173574 DOI: 10.1016/j.ijid.2020.03.017]

25 **Rodriguez-Morales AJ**, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A, Lagos-Grisales GJ, Ramírez-Vallejo E, Suárez JA, Zambrano LI, Villamil-Gómez WE, Balbin-Ramon GJ, Rabaan AA, Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis* 2020; **34**: 101623 [PMID: 32179124 DOI: 10.1016/j.tmaid.2020.101623]

26 **Kisely S**, Warren N, McMahon L, Dalais C, Henry I, Siskind D. Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis. *BMJ* 2020; **369**: m1642 [PMID: 32371466 DOI: 10.1136/bmj.m1642]

27 **Alqahtani JS**, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, Quaderi S, Mandal S, Hurst JR. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. *PLoS One* 2020; **15**: e0233147 [PMID: 32392262 DOI: 10.1371/journal.pone.0233147]

28 **Zhong H**, Wang Y, Zhang ZL, Liu YX, Le KJ, Cui M, Yu YT, Gu ZC, Gao Y, Lin HW. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. *Pharmacol Res* 2020; **157**: 104872 [PMID: 32360583 DOI: 10.1016/j.phrs.2020.104872]

29 **Etoom M**, Alwardat S, Alwardat M. Issues for conducting meta-analyses in COVID-19. Commentary on "Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis''. *J Clin Virol* 2020; **128**: 104389 [PMID: 32387969 DOI: 10.1016/j.jcv.2020.104389]

30 **Hu Y**, Sun J, Dai Z, Deng H, Li X, Huang Q, Wu Y, Sun L, Xu Y. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Virol* 2020; **127**: 104371 [PMID: 32315817 DOI: 10.1016/j.jcv.2020.104371]

31 **Ford N**, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. *J Int AIDS Soc* 2020; **23**: e25489 [PMID: 32293807 DOI: 10.1002/jia2.25489]

32 **Pedersen SF**, Ho YC. SARS-CoV-2: a storm is raging. *J Clin Invest* 2020; **130**: 2202-2205 [PMID: 32217834 DOI: 10.1172/JCI137647]

33 **Valk SJ**, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. *Cochrane Database Syst Rev* 2020; **5**: CD013600 [PMID: 32406927 DOI: 10.1002/14651858.CD013600]

34 **AminJafari A**, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. *Int Immunopharmacol* 2020; **83**: 106455 [PMID: 32272396 DOI: 10.1016/j.intimp.2020.106455]

35 **Zhang Q**, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. *J Med Virol* 2020; **92**: 540-545 [PMID: 32108352 DOI: 10.1002/jmv.25733]

36 **Keyaerts E**, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. *Antimicrob Agents Chemother* 2009; **53**: 3416-3421 [PMID: 19506054 DOI: 10.1128/AAC.01509-08]

37 **Chowdhury MS**, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. *Acad Emerg Med* 2020; **27**: 493-504 [PMID: 32359203 DOI: 10.1111/acem.14005]

38 **Shah S**, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). *Int J Rheum Dis* 2020; **23**: 613-619 [PMID: 32281213 DOI: 10.1111/1756-185X.13842]

39 **Das S**, Bhowmick S, Tiwari S, Sen S. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). *Clin Drug Investig* 2020; **40**: 591-601 [PMID: 32468425 DOI: 10.1007/s40261-020-00927-1]

40 **Cortegiani A**, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care* 2020; **57**: 279-283 [PMID: 32173110 DOI: 10.1016/j.jcrc.2020.03.005]

41 **Yang Z**, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. *J Infect* 2020; **81**: e13-e20 [PMID: 32283144 DOI: 10.1016/j.jinf.2020.03.062]

42 **Ye Z**, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg B, Yao L, Motaghi S, Couban RJ, Ghadimi M, Bala MM, Gomaa H, Fang F, Xiao Y, Guyatt GH. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. *CMAJ* 2020; **192**: E756-E767 [PMID: 32409522 DOI: 10.1503/cmaj.200645]

43 **Li H**, Chen C, Hu F, Wang J, Zhao Q, Gale RP, Liang Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. *Leukemia* 2020; **34**: 1503-1511 [PMID: 32372026 DOI: 10.1038/s41375-020-0848-3]

44 **Veronese N**, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, Lagolio E, Celotto S, Pizzol D, Zou L, Tully MA, Ilie PC, Trott M, López-Sánchez GF, Smith L. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. *Front Med (Lausanne)* 2020; **7**: 170 [PMID: 32391369 DOI: 10.3389/fmed.2020.00170]

45 **Zhang JJY**, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. *Clin Infect Dis* 2020; **71**: 2199-2206 [PMID: 32407459 DOI: 10.1093/cid/ciaa576]

46 **Nasir M**, Talha KA, Islam T, Saha SK, Selina F, Parveen RA. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences. *Mymensingh Med J* 2020; **29**: 481-487 [PMID: 32506110]

47 **Li Z**, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. *Drug Discov Ther* 2020; **14**: 73-76 [PMID: 32378648 DOI: 10.5582/ddt.2020.01015]

48 **Grover A**, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. *Eur Heart J Cardiovasc Pharmacother* 2021; **7**: 148-157 [PMID: 32542337 DOI: 10.1093/ehjcvp/pvaa064]

49 **Zhang X**, Yu J, Pan LY, Jiang HY. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. *Pharmacol Res* 2020; **158**: 104927 [PMID: 32422341 DOI: 10.1016/j.phrs.2020.104927]

50 **Ang L**, Song E, Lee HW, Lee MS. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Med* 2020; **9** [PMID: 32456123 DOI: 10.3390/jcm9051583]

51 **Bidra AS**, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. *J Prosthodont* 2020; **29**: 529-533 [PMID: 32511851 DOI: 10.1111/jopr.13209]

52 **Phan T**. Genetic diversity and evolution of SARS-CoV-2. *Infect Genet Evol* 2020; **81**: 104260 [PMID: 32092483 DOI: 10.1016/j.meegid.2020.104260]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no potential conflict of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** American Association for Cancer Research, No. 229378.

**Peer-review started:** January 14, 2021

**First decision:** March 1, 2021

**Article in press:** May 17, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cassell III AK **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Li X

**Figure Legends**



**Figure 1 Coronavirus disease 2019 and its possible treatments.** COVID-19: Coronavirus disease 2019; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; IgG: Immunoglobulin G.

**Table 1 Synthetic of evidence on coronavirus disease 2019 specific therapeutic strategies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Nature of therapeutics** | **PMID** | **Study type** | **Therapeutic** | **Benefits** | **Conclusion** |
| Anti-viral drugs | 32360583 | SR | Lopinavir-ritonavir or ribavirin | Improved mortality rate, radiographical improvement and reduced clinical development | Inconclusive evidences, low quality of evidence and heterogeneity of interventions |
| 32309809 | Lopinavir-ritonavir or Arbidol or Oseltamivir or Lianhuaqingwen capsule or interferon | No benefits in 199 subjects | Side effects. Inconclusive evidence lacks of data recording. Sample size |
| 32493740 | SR & MA |
| 32293807 | SR | Lopinavir-ritonavir | No clinical benefits | Adverse side effects. Inconclusive outcomes. Low body of evidence. Small sample size |
| 32506110 | Remdesivir | No clinical benefits | Inconclusive outcomes high-quality evidence well-designed studies. Safety |
| 32378648 |
| Immune therapy | 32406927 | SR | Plasma transfusion | Had beneficial outcomes | Side effects. Inconclusive outcomes. Very low-certainty. High risk of bias. Low reporting quality |
| 32272396 | Plasma therapy or hyperimmune immunoglobulin transfusion | Had beneficial outcomes | More evidence. Promising strategy. Sample size. Lack of control group |
| 32527348 |
| Anti-malaria drugs | 32359203 | SR | Hydroxychloroquine/Chloroquine | Had beneficial outcomes | Inconclusive outcomes. Methodological flaws. Risk of bias. Lack of evidence |
| 32281213 | No clinical benefits | Lack of evidence. Safety issues |
| 32468425 | Methodological flaws. Small sample size. Safety issues |
| 32173110 | Lack of evidence. Safety issues. Methodological flaws. Small sample size |
| 32519281 |
| Hormone therapy | 32283144 | SR & MA | Corticosteroids | No clinical benefits | Lack of evidence. Adverse side effects. Methodological flaws. Caution needed |
| 32409522 | SR |
| 32372026 |
| 32391369 |
| Anti-hypertension drugs | 32542337 | SR & MA | ACEI/ARB | Had beneficial outcomes | Conflicting results, scarce existing data. Diverse study types. Inconsistent clinical studies, more RCT needed |

ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin-receptor blockers; RCT: Randomised controlled trial; SR: Systematic reviews; MA: Meta-analysis.

**Table 2 Vaccines specific to severe acute respiratory syndrome coronavirus 2 under clinical investigation and their development status**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Vaccine name** | **Vaccine type** | **Status** | **Registration ID** | **Date of registration** | **Developer** |
| 2019-nCOV | Adenovirus vaccine | Phase II | ChiCTR2000031781 | 10-Apr-20 | Academy of Military Medical Sciences |
| Ad5-nCoV | Adenovirus vaccine | Phase II | NCT04341389 | 10-Apr-20 | CanSino Biologics |
| AV-COVID-19 | Autologous dendritic cells | Phase IB/II | NCT04386252 | 13-May-20 | Aivita Biomedical, Inc |
| BBIBP-CorV | Inactivated virus | Phase I/II | ChiCTR2000032459 | 29-Apr-20 | Beijing Institute of Biological Products & Sinopharm |
| BNT162 | mRNA vaccine | Phase I/II | NCT04380701 | 8-May-20 | BioNTech and Pfizer |
| ChAdOx1 | Adenovirus vaccine | Phase II/III | NCT04400838 | 26-May-20 | University of Oxford |
| Covax-19™ | SARS-CoV-2 spike protein | Phase I | NCT04428073 | 11-Jun-20 | GeneCure Biotechnologies |
| COVID-19/aAPC | Antigen presenting cells | Phase I | NCT04299724 | 9-Mar-20 | Shenzhen Geno-Immune Medical Institute |
| INO-4800 | DNA vaccine | Phase I | NCT04336410 | 7-Apr-20 | Inovio Pharmaceuticals |
| LV-SMENP-DC | Lentiviral vector system | Phase I/II | NCT04276896 | 19-Feb-20 | Shenzhen Geno-Immune Medical Institute |
| mRNA-1273 | mRNA vaccine | Phase II | NCT04405076 | 28-May-20 | ModernaTX, Inc |
| NVX-CoV2373 | Recombinant Spike Protein | Phase I/II | NCT04368988 | 30-Apr-20 | Novavax |
| PiCoVacc | Inactivated virus + adjuvant | Phase I/II | NCT04352608 | 20-Apr-20 | Sinovac |
| V- SARS | Heat-inactivated plasma | Phase I/II | NCT04380532 | 8-May-20 | Immunitor LLC |
| Vero cells | Inactivated virus | Phase I/II | ChiCTR2000031809 | 11-Apr-20 | Wuhan Institute of Biological Products & Sinopharm |

LLC: Lewis lung carcinoma; COVID-19: Coronavirus disease 2019; SARS: Severe acute respiratory syndrome.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**